Clinical Trial News and Research

RSS

NanoLogix to move R&D operations from Cincinnati to its headquarters in Hubbard

NanoLogix, an innovator in the accelerated detection and identification of microorganisms, announced today it will move its research and development operations from Cincinnati to its headquarters in Hubbard, Ohio.

6 Sep 2011

NOXXON to commence NOX-H94 Phase I trial in anemia of chronic disease

NOXXON Pharma today announced the initiation of a Phase I clinical trial for NOX-H94, the Company's third compound to enter the clinic. NOX-H94 is a Spiegelmer designed to treat anemia of chronic disease by targeting the peptide hormone hepcidin, the key regulator of iron metabolism.

6 Sep 2011

Chondroitin sulfate decreases pain and improves hand function in patients with OA

New research shows that chondroitin sulfate significantly decreased pain and improved hand function in patients with osteoarthritis (OA) of the hand compared with those in the placebo group. Results of the clinical trial available today in Arthritis & Rheumatism, a journal published by Wiley-Blackwell on behalf of the American College of Rheumatology (ACR), also report that chondroitin sulfate improves grip strength and relieves morning stiffness.

6 Sep 2011

BioAlliance Pharma announces oral communication of Livatag Phase II trial results on liver cancer

BioAlliance Pharma SA, a company dedicated to specialty and orphan oncology products, today announces oral communication of the Phase II clinical trial results of its orphan product Livatag at the annual congress of ILCA, the only international organization devoted exclusively to liver cancer research with participation of worldwide best specialists.

6 Sep 2011

Mesoblast receives EMA clearance to initiate Revascor Phase 2 trial for heart attacks

Global regenerative medicine company, Mesoblast Limited, today announced that it had received clearance from the European Medicines Agency (EMA) to begin a 225-patient multi-center Phase 2 clinical trial in Europe for its lead cardiovascular product Revascor(TM) in conjunction with angioplasty and stent procedures to prevent heart failure after a major heart attack.

5 Sep 2011

Australia’s Mesoblast receives nod to start first European trial of allogeneic stem cell treatment for heart attacks

Global regenerative medicine company, Mesoblast Limited, (ASX: MSB), today announced that it had received clearance from the European Medicines Agency (EMA) to begin a 225-patient multi-center Phase 2 clinical trial in Europe for its lead cardiovascular product Revascor™ in conjunction with angioplasty and stent procedures to prevent heart failure after a major heart attack. Revascor™ is an allogeneic, or “off-the-shelf”, adult stem cell product derived from Mesoblast's proprietary Mesenchymal Precursor Cell (MPC) platform technology which is being developed for use in a range of cardiovascular diseases including congestive heart failure, chronic angina, and heart attacks (acute myocardial infarction).

5 Sep 2011

C. sporogenes bacterium could be used as vehicle to deliver drugs in frontline cancer therapy

A bacterial strain that specifically targets tumours could soon be used as a vehicle to deliver drugs in frontline cancer therapy. The strain is expected to be tested in cancer patients in 2013 says a scientist at the Society for General Microbiology's Autumn Conference at the University of York.

5 Sep 2011

SWOG selects four cancer researchers for 2011 Young Investigator Training Course

SWOG has selected four talented, early-career researchers for its 2011 Young Investigator Training Course. These four will attend a three-day workshop September 19 - 21 in Seattle, Wash., for intensive training in how to design and conduct cancer clinical trials.

3 Sep 2011

Jefferson's two-step bone marrow transplant procedure holds promise for cancer patients

Half-matched bone marrow or stem cell transplants for blood cancer patients have typically been associated with disappointing clinical outcomes. However, a clinical trial conducted at the Kimmel Cancer Center at Jefferson testing its unique, two-step half-match procedure has produced some promising results: the probability of overall survival was 45 percent in all patients after three years and 75 percent in patients who were in remission at the time of the transplant.

2 Sep 2011

Mayo Clinic and IC-MedTech enter collaborative research agreement with Summa Health System

Researchers from the Mayo Clinic and representatives from IC-MedTech signed a collaborative research agreement with Summa Health System to study the usage of Apatone, a proprietary combination of Vitamin-C and Vitamin-K3.

2 Sep 2011

Valproic acid may increase survival for brain tumor patients

New research suggests brain tumor patients who take the seizure drug valproic acid on top of standard treatment may live longer than people who take other kinds of epilepsy medications to control seizures.

2 Sep 2011

UTHealth to study BMS-820836 in Phase II trial for major depressive disorder

A new medication to treat major depressive disorder in patients who have not responded to other antidepressants is being studied in a Phase II clinical trial by researchers at The University of Texas Health Science Center at Houston.

2 Sep 2011

Positive results from Bionovo's Menerba tolerability trial on menopausal hot flashes

Bionovo, Inc., a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, today announced the positive results from the completion of their tolerability trial of Menerba (MF101) for menopausal hot flashes.

31 Aug 2011

Enrollment commences in Adamis' APC-100 Phase 1/2a clinical prostate study

Adamis Pharmaceuticals Corporation announced today that it enrolled the first patient in its Phase 1/2a clinical prostate study. Adamis' drug, APC-100, will be used to treat men with castrate-resistant prostate cancer.

31 Aug 2011

Bristol-Myers Squibb selects ICON as preferred provider for early phase clinical development

ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that it has been chosen by Bristol-Myers Squibb Company as a preferred provider for full-service clinical pharmacology and exploratory clinical studies.

30 Aug 2011

BIOTRONIK Home Monitoring reduces inappropriate shocks, improves ICD battery longevity

BIOTRONIK, a leading manufacturer of implantable cardiac devices and the pioneer of wireless remote monitoring technology, announced today the first presentation of results from the ECOST randomized controlled trial.

30 Aug 2011

St. John Hospital enrolls first patient in Moxy- Drug Coated Balloon trial for PAD

Physicians at St. John Hospital and Medical Center have enrolled the first patient in Michigan in LEVANT2, a global, multicenter, randomized clinical trial evaluating the safety and effectiveness of the Moxy- Drug Coated Balloon for the treatment of peripheral arterial disease.

30 Aug 2011

Clinical trial to evaluate RMN system for treatment of ischemic Ventricular Tachycardia

Results from the STOP-VT Study were presented at the ESC Congress 2011 today. This is the first ever multi-center, global, prospective trial to evaluate a Remote Magnetic Navigation system for the treatment of ischemic Ventricular Tachycardia.

30 Aug 2011

Ivabradine reduces heart volume among patients with cardiac insufficiency

As guest speaker at the European Society of Cardiology's Congress currently under way in Paris, Dr. Jean-Claude Tardif, Director of the Montreal Heart Institute's Research Centre and professor of medicine at the Universit- de Montr-al, today presented the results of an analysis demonstrating that ivabradine, a medication used to reduce heart rate, also reduces heart volume (left ventricle) among patients with cardiac insufficiency.

30 Aug 2011

Post myocardial infarction snus quitters have 44% lower risk of mortality

In this prospective cohort study, presented today at the ESC Congress 2011, discontinuation of smokeless tobacco after a myocardial infarction (MI) is associated with a lower risk of subsequent mortality. Investigators found that post MI snus quitters had a 44 % lower risk of total mortality.

29 Aug 2011

Clinical Trial News and Research

NanoLogix to move R&D operations from Cincinnati to its headquarters in Hubbard

NOXXON to commence NOX-H94 Phase I trial in anemia of chronic disease

Chondroitin sulfate decreases pain and improves hand function in patients with OA

BioAlliance Pharma announces oral communication of Livatag Phase II trial results on liver cancer

Mesoblast receives EMA clearance to initiate Revascor Phase 2 trial for heart attacks

Australia’s Mesoblast receives nod to start first European trial of allogeneic stem cell treatment for heart attacks

C. sporogenes bacterium could be used as vehicle to deliver drugs in frontline cancer therapy

SWOG selects four cancer researchers for 2011 Young Investigator Training Course

Jefferson's two-step bone marrow transplant procedure holds promise for cancer patients

Mayo Clinic and IC-MedTech enter collaborative research agreement with Summa Health System

Valproic acid may increase survival for brain tumor patients

UTHealth to study BMS-820836 in Phase II trial for major depressive disorder

Positive results from Bionovo's Menerba tolerability trial on menopausal hot flashes

Enrollment commences in Adamis' APC-100 Phase 1/2a clinical prostate study

Bristol-Myers Squibb selects ICON as preferred provider for early phase clinical development

BIOTRONIK Home Monitoring reduces inappropriate shocks, improves ICD battery longevity

St. John Hospital enrolls first patient in Moxy- Drug Coated Balloon trial for PAD

Clinical trial to evaluate RMN system for treatment of ischemic Ventricular Tachycardia

Ivabradine reduces heart volume among patients with cardiac insufficiency

Post myocardial infarction snus quitters have 44% lower risk of mortality

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

BFEB: Advances in microplate-based assays and analysis

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery